Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease

Hepatitis C (HCV) is a leading cause of chronic liver disease worldwide and its prevalence in hemodialysis patients is higher than that of general population. There are no approved direct acting antiviral treatments to date in this population. We describe our experience of open label treatment with simeprevir and half-dose sofosbuvir in 15 HCV GT1 patients with end stage renal disease (ESRD), defined as glomerular filtration rate (GFR) of ⩽30 ml/min per 1.73 m2 or requirement for dialysis. Corrigendum to “Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease” [J Hepatol 2015;63:763–765]Journal of HepatologyVol. 63Issue 6PreviewIn the original Letter to the Editor the authors names were reversed, surname appeared before first name, the correct order of authors’ names are above. In addition, for clarity Fig. 1 has been modified, see below. Full-Text PDF